Medtronic PLC MDT

Morningstar Rating
Add To Portfolio
|%
Chart Data Not Available
  • Last Close
  • Sector
  • Industry
  • Investment Style
    Large Value
  • Market Cap
  • Forward Div Yield
    3.24%
  • Trailing Div Yield
  • Price/Sales
    3.44
  • Price/Book
    2.29
  • Beta (5-Year)
    0.80
  • Consensus Forward P/E
    15.87
  • Trailing 12-mo Rev

Morningstar's Analysis

Valuation Nov 22, 2022
Currency in USD
Is it the right time to buy or sell?
Fair ValueLearn Moreplay
1-Star Price
Premium
Economic Moat
Premium
5-Star Price
Premium
Capital Allocation
Premium
Medtronic Earnings: New Spinoff of Diabetes Business to Aid in Raising Profitability
Author Photo
Debbie S. Wang
Senior Equity Analyst
Analyst Note | by Debbie S. Wang Updated May 21, 2025

Medtronic delivered another quarter of solid, consistent results with revenue and adjusted EPS up 5% and 11%, respectively. It also announced plans to spin off its diabetes business within 18 months.

Business Strategy and Outlook | by Debbie S. Wang Updated Mar 12, 2025

Medtronic's standing as the largest pure-play medical-device maker remains a force to be reckoned with in the med-tech landscape. Medtronic's diversified product portfolio aimed at a wide range of chronic diseases spans therapeutic areas including cardiac, diabetes, chronic pain, as well as various products for acute care. This has put Medtronic in

Morningstar Fair Value Estimate
The Morningstar Fair Value Estimate guides investors to the long-term, intrinsic value of a stock, helping them see beyond the present market price.

Show me how fair value is derived (00:41)

Morningstar calculates the fair value estimate of a company based on a projection of how much cash the company will generate in the future. Morningstar analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. The analyst discounts future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights.

The Morningstar Fair Value Estimate is a projection/opinion and not a statement of fact. If Morningstar's base-case assumptions are true the market price will converge on Morningstar's fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in the future and is no indication of future performance.

Morningstar Equity Research Methodology

Price vs. Fair Value

Related

Morningstar Research
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy       Disclosures        Accessibility